Annual rank1
Poland · Healthcare
Synektik
Provides products, services and IT solutions for surgery, imaging diagnostics, nuclear medicine and healthcare robotics.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Robotics, PET tracers and software for clinical workflows
Synektik is a Polish healthcare-technology group operating across surgical robotics, diagnostic imaging, nuclear medicine and medical IT. It combines its own PET radiopharmaceuticals and software with selected systems from international manufacturers, then supplies the engineering, installation, training, testing and service needed to make those technologies work inside hospitals across Central Europe and the Baltic states.
Robotics and precision medicine
From a lung-biopsy route map to robotic surgery
Synektik distributes Intuitive's da Vinci surgical systems and introduced the Ion robotic platform in Poland for navigating to hard-to-reach lung nodules. Its wider portfolio also covers Symani microsurgery, ZAP-X radiosurgery and MR-guided focused-ultrasound neurosurgery with Exablate Neuro.
- Ion robotic bronchoscopy A 3D airway map, shape-sensing catheter and lung-biopsy workflow
- da Vinci robotic surgery System components, clinical fields and Synektik support
- ▶ VideoWatch: da Vinci procedure Language-neutral surgical footage embedded by Synektik
- Intuitive partnership Exclusive distribution through 2031, including Ukraine
- Symani microsurgery Robotic microsurgery and supermicrosurgery for vessels, nerves and lymphatic structures
- ZAP-X and MRgFUS Radiosurgery and focused-ultrasound neurosurgery in Synektik's neurology portfolio
Radiopharmaceuticals
Short-lived PET tracers made at three cyclotron sites
Synektik Pharma manufactures and distributes tracers used in PET diagnostics from Kielce, Warsaw and Mszczonów. The listed portfolio includes products for oncology, cardiology and neurology; its Clinical Trials Center can also synthesise novel tracers on demand and arrange land or air delivery to study sites.
- Radiopharmaceutical portfolio Named PET tracers, indications and three production locations
- Clinical Trials Center Custom synthesis, regulatory support and dose delivery for studies
- Radiopharmacy capabilities Synektik Pharma products, devices and clinical-trial services
Medical software and AI
Move images, results and radiation records through one workflow
ArPACS brings PACS, RIS and image-viewing modules into a radiology environment. Zbadani.pl connects imaging centres, clinicians and patients through DICOM-compatible records and secure result sharing, while SynDose tracks ionising-radiation doses. Synektik works with Carebot on AI support for mammography and chest X-ray analysis. In August 2026, their consortium signed two contracts with Poland’s Centre for e-Health (CeZ), totalling PLN 24.2m, for AI models covering mammography and chest X-rays. Carebot supplies the models; Synektik handles integration with the Intelligent Services Platform, network deployment and ongoing maintenance.
- ArPACS Synektik's PACS, RIS and diagnostic-image environment
- Zbadani.pl A browser-based pathway for images, results and consultations
- SynDose Monitoring and reporting ionising-radiation doses
- AI imaging applications Carebot mammography and X-ray models, plus BrainScan CT
- CeZ AI contracts 28 August 2026: two signed contracts, PLN 24.2m total (Polish)
Hospital integration and service
A technology sale can begin with construction work
A turnkey project can include room adaptation, imaging or therapy equipment, PACS/RIS deployment, diagnostic workstations and staff training. Synektik also supplies BD Rowa storage-and-dispensing robots and APOTECAchemo systems for automated oncology-drug preparation, then maintains specialised devices across Poland, Czechia and Slovakia and is extending its service footprint into the Baltic states after securing its first Baltic equipment order in 2026.
- Turnkey clinical delivery Equipment, room adaptation, software, workstations and training
- Imaging integration Diagnostic-laboratory planning and authorised equipment supply
- Technical services IT support, medical-equipment maintenance and specialist tests
- Accredited equipment tests Acceptance and specialist measurements for X-ray and nuclear medicine
- Baltic expansion The regional company serving Lithuania, Latvia and Estonia
- Hospital-pharmacy automation BD Rowa storage and APOTECAchemo preparation in a hospital implementation
Official profile sources: Synektik is the world’s leading distributor of da Vinci robotic surgery systems · Record-breaking year and fourth quarter in the Synektik Group · About Synektik Group · System robotyczny do mikrochirurgii Symani w Krakowie
Editorial correction, 10 September 2026: updated the AI partnership and CeZ contract information following company clarification and checks against public sources. Annual ranking unchanged.
Current 2026 update
What is changing at Synektik in 2026?
The final nine-month report confirms that hospital deliveries are expanding Synektik's installed base and follow-on service business. Synektik reports that Edison now has European clearance; the first Baltic equipment contract has been secured, Ukraine is being prepared and drug R&D has moved to Syn2Bio.
The change in one sentence
Scale is turning equipment delivery into a regional installed-base business.
Synektik is selling more systems, but the strategic change is what follows: a larger serviced fleet, repeat demand for instruments and software, new therapy platforms and a wider geographic service footprint.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Installed-base flywheel
The da Vinci fleet reached 142 systems, and follow-on revenue is compounding
Synektik sold 28 da Vinci systems in the first nine months of its financial year. At 30 June, 142 authorised da Vinci systems operated across Poland, Czechia and Slovakia, all under group maintenance agreements. What Synektik calls recurring revenue - maintenance, warranty and IT services plus consumable instruments and accessories - rose 28% to PLN 291.0m over nine months; the trailing-twelve-month figure reached PLN 374.7m, up 32%.
- Current signal142 da Vinci systems · PLN 291m issuer-defined recurring revenue
- Why it mattersEach installation can add years of maintenance, software and procedure-material demand, so utilisation and service attachment matter alongside new-system sales.
- Nine-month report Synektik · 2026-08-05
02 · Platform launch and regional execution
Edison is CE-certified; Baltic sales have started and Ukraine is next
Synektik says Edison obtained CE certification in July, authorising commercialisation and use in the EU. The group registered its Kyiv subsidiary, is building the local team and planned to begin Ukrainian operations around the start of calendar Q4 2026. Its Intuitive agreement now runs through 31 December 2031 and grants exclusivity in Ukraine. In the already-covered Baltic territory, a da Vinci contract with University Hospital Kaunas became the group's first medical-equipment order.
- Current signalEdison CE certification · Ukraine planned for calendar Q4
- Why it mattersThe test is whether Synektik can turn existing Baltic rights and the new Ukrainian territory into installed systems, training and dependable local service.
- Nine-month report Synektik · 2026-08-05
- Intuitive agreement Synektik · 2026-02-02
03 · Sharper listed group
Syn2Bio's separation makes operating performance easier to read
The final statements report nine-month revenue of PLN 733.4m and net profit from continuing operations of PLN 138.0m. Total net profit of PLN 386.4m reflects continuing profit plus a PLN 261.3m demerger gain, net of a PLN 12.9m loss from the separated business. The cardiotracer project and new-molecule R&D now sit in Syn2Bio, while commercial medtech and radiopharmaceutical activities remain in Synektik.
- Current signalPLN 138m continuing profit
- Why it mattersFuture performance should be read through continuing operations and the mix of equipment, services and commercial radiopharmaceuticals, not the one-off demerger gain.
- Nine-month report Synektik · 2026-08-05
- Syn2Bio spin-off Synektik · 2026-05-14
04 · What to watch
Three questions for the next disclosures
Three questions distinguish installed-base compounding from a strong delivery period.
- Demand conversionHow quickly does PLN 44.2m of confirmed backlog convert, and how much of PLN 160.8m in active offers is won, after nine-month order intake of PLN 423.0m?
- New-market executionDoes Edison move from certification to hospital adoption, does the planned Ukraine launch begin around calendar Q4 2026, and does the first Baltic order lead to further deployments?
- Flywheel qualityDo recurring revenue and operating cash flow remain strong as the installed base grows and large equipment deliveries change the quarterly mix?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 1 | +364% | +1028% | +875% |